SPINOCEREBELLAR ATAXIA TYPE 7
Clinical trials for SPINOCEREBELLAR ATAXIA TYPE 7 explained in plain language.
Never miss a new study
Get alerted when new SPINOCEREBELLAR ATAXIA TYPE 7 trials appear
Sign up with your email to follow new studies for SPINOCEREBELLAR ATAXIA TYPE 7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could slow rare brain disease that steals balance
Disease control OngoingThis phase 3 trial tests whether the drug troriluzole can slow the progression of spinocerebellar ataxia, a rare genetic disorder that affects coordination and balance. About 300 adults with different types of SCA are randomly assigned to take either troriluzole or a placebo dail…
Matched conditions: SPINOCEREBELLAR ATAXIA TYPE 7
Phase: PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a drug slow rare brain disease? new study uses Real-World data to find out
Disease control OngoingThis study looks at whether the drug troriluzole can slow the progression of spinocerebellar ataxia (SCA), a rare genetic disease that affects movement and balance. Researchers will compare 909 patients who took troriluzole for up to three years with similar patients who did not …
Matched conditions: SPINOCEREBELLAR ATAXIA TYPE 7
Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New study tracks rare disease SCA7 to uncover clues for future treatments
Knowledge-focused OngoingThis study follows 25 people with spinocerebellar ataxia type 7 (SCA7) for up to 5 years to learn how the disease changes vision, coordination, and thinking. Participants will have yearly eye exams, brain scans, and neurological tests. No treatment is given; the goal is to gather…
Matched conditions: SPINOCEREBELLAR ATAXIA TYPE 7
Sponsor: National Eye Institute (NEI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC